DDW 2015

  1. Younossi Z, Bacon BR, Dieterich D, Flamm SL, Kowdley K, Lawitz E, Milligan S and Tsai N. Evaluation of access to care in patients prescribed sofosbuvir-containing regimens: data from the TRIO network. Gastroenterology 2015; 148(4): S1090.
  2. Dieterich D, Bacon BR, Flamm SL, Kowdley K, Milligan S, Tsai N, Younossi Z and Lawitz E. Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the TRIO network; Academic and community treatment of a real-world, heterogeneous population. Gastroenterology 2015; 148(4): S1001.
  3. Tsai N, Bacon BR, Flamm SL, Kowdley K, Lawitz E, Milligan S, Younossi Z and Dieterich D. Comparison of sofosbuvir +/- simeprevir in heterogeneous, real-world populations of HCV patients over 70 years; data from the TRIO network. Gastroenterology 2015; 148(4): S1085.
  4. Kowdley K, Bacon BR, Dieterich D, Lawitz E, Milligan S, Tsai N, Younossi Z and Flamm SL. Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of Genotype 3 HCV; data from the TRIO network. Gastroenterology 2015; 148(4): S1087.

 

EASL 2015

  1. Dieterich D, Bacon BR, Flamm SL, Kowdley K, Milligan S, Tsai N, Younossi Z and Lawitz E. Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Journal of Hepatology 62(Suppl 2): P0775
  2. Tsai N, Bacon BR, Flamm SL, Kowdley K, Lawitz E, Milligan S, Younossi Z and Dieterich D. Comparison of sofosbuvir +/- simeprevir in heterogeneous, real-world populations of HCV patients over 70 years; data from the TRIO network. Journal of Hepatology 62(Suppl 2): P0787
  3. Kowdley K, Bacon BR, Dieterich D, Lawitz E, Milligan S, Tsai N, Younossi Z and Flamm SL. Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of Genotype 3 HCV; data from the TRIO network. Journal of Hepatology 62(Suppl 2): P0867

 

AASLD 2014

  1. Bacon BR, Dieterich D, Flamm SL, , Kowdley K, Lawitz E, Milligan S, Tsai N and Younossi Z. Efficacy of sofosbuvir and simeprevir-based regimens for HCV treatment-experienced GT1 Patients in a real-life setting; data from the TRIO network. Hepatology 2014; 60: 672A.
  2. Dieterich D, Bacon BR, Flamm SL, Kowdley K, Milligan S, Tsai N, Younossi Z and Lawitz E. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network; Academic and community treatment of a real-world, heterogeneous population. Hepatology 2014; 60: 46.
  3. Flamm SL, Bacon BR, Dieterich D, Kowdley K, Lawitz E, Milligan S, Younossi Z and Tsai N. Evaluation of efficacy of sofosbuvir and simeprevir-based regimens in a real-life population of 345 HCV patients with cirrhosis; data from the TRIO network. Hepatology 2014; 60(S1): 677A.